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Abstract
We previously showed that betaxolol, a selective β1-adrenergic receptor antagonist, administered 
during early phases of cocaine abstinence, ameliorated withdrawal-induced anxiety and blocked 
increases in amygdalar β1-adrenergic receptor expression in rats. Here, we report the efficacy of 
betaxolol in reducing increases in gene expression of amygdalar corticotropin-releasing factor 
(CRF), a peptide known to be involved in mediating ‘anxiety-like’ behaviors during initial phases 
of cocaine abstinence. We also demonstrate attenuation of an amygdalar β1-adrenergic receptor-
mediated cell signaling pathway following this treatment. Male rats were administered betaxolol at 
24 and 44 hours following chronic cocaine administration. Animals were euthanized at the 48 hour 
time-point and the amygdala was micro-dissected and processed for quantitative reverse 
transcriptase-polymerase chain reaction (qRT-PCR) and/or Western blot analysis. Results showed 
that betaxolol treatment during early cocaine withdrawal attenuated increases in amygdalar CRF 
gene expression and cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) 
regulatory and catalytic subunit (nuclear fraction) protein expression. Our data also reveal that β1-
adrenergic receptors are on amygdalar neurons which are immunoreactive for CRF. The present 
findings suggest that the efficacy of betaxolol treatment on cocaine withdrawal-induced anxiety 
may be related, in part, to its effect on amygdalar β1-adrenergic receptor, modulation of its 
downstream cell signaling elements and CRF gene expression.
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Introduction
Cessation of cocaine intake following chronic drug exposure is typically characterized by 
anxiety, depression, fatigue and agitation (NIDA, 2007). Importantly, anxiety induced 
during early phases of cocaine abstinence is often a provoking factor leading to relapse to 
cocaine use in human addicts (Gawin and Kleber, 1986; Koob and Bloom, 1988). 
Corticotropin-releasing factor (CRF) is a neuropeptide widely distributed in 
extrahypothalamic-limbic brain areas, such as the amygdala, and has been implicated in 
mediating the ‘anxiety-like’ behavior that is observed in animals during the initial phase of 
cocaine abstinence (Sarnyai et al, 1995; Zhou et al, 2003). Animal studies have 
demonstrated that CRF protein expression is significantly elevated in the amygdala, a brain 
region rich in numerous CRF neurons, during early cocaine withdrawal (2 days) from 
chronic cocaine exposure (Sarnyai et al, 1995). Additionally, significant increases in 
amygdalar CRF gene expression have also been reported to occur in animals during this 
early withdrawal time-period (Zhou et al, 2003). Taken together, these findings indicate 
amygdalar CRF as a potential substrate underlying the expression of anxiety-like behavior 
that has been exhibited by animals during early cocaine withdrawal (Zhou et al, 2003).
The amygdala, a subcortical limbic structure that receives prominent noradrenergic 
innervation from the brainstem (Clayton and Williams, 2000; Pitkanen, 2000), shows a 
significant up-regulation of β1-adrenergic receptor expression following 2 days of 
withdrawal from chronic cocaine treatment (Rudoy and Van Bockstaele, 2006). β1-
adrenergic receptor expression levels return to that of controls following a more extended 
withdrawal period (12 days) (Rudoy and Van Bockstaele, 2006). Interestingly, 
administration of the selective β1-adrenergic receptor antagonist, betaxolol (Mosby, 2006), 
during early cocaine withdrawal significantly diminished cocaine withdrawal-related 
anxiety-like behavior in the animals and also reduced β1-adrenergic receptor expression 
levels such that they were comparable to controls (Rudoy and Van Bockstaele, 2006). The 
β1-adrenergic receptor is coupled to Gs (stimulatory G-protein), an effect leading to 
increases in intracellular cyclic adenosine monophosphate (cAMP) levels via activation of 
adenylate cyclase (Schultz and Daly, 1973). We postulated that downstream targets of the 
β1-adrenergic receptor, cyclic-AMP-dependent protein kinase (PKA) regulatory subunit, 
PKA catalytic subunit, cAMP response element binding protein (CREB) and phosphorylated 
CREB (pCREB), would show alterations in expression in rat amygdala extracts following 
early cocaine withdrawal, as well as, following betaxolol treatment during early cocaine 
withdrawal. Therefore, we tested this hypothesis here. In order to evaluate the activation of 
PKA, we first performed an extraction procedure in which the nuclear compartment of our 
amygdalar micro-dissections were separated from cytoplasmic components. Next, we 
prepared these fractionated extracts for Western blotting, and probed them using antibodies 
targeted towards the regulatory and/or catalytic subunits of PKA.
To further elucidate gene targets accompanying cell signaling alterations in the amygdala, 
we focused on CRF gene expression. CRF is implicated in a number of drug abstinence 
syndromes and relapse to drug-seeking for multiple drugs of abuse, such as marijuana 
(Bruijnzeel and Gold, 2005), nicotine (Bruijnzeel et al, 2007), opioids (Sarnyai et al, 2001), 
alcohol (Menzaghi et al, 1994) and cocaine (Sarnyai et al, 1995; Weiss et al, 2001; Pollandt 
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et al, 2006). Using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), 
we examined CRF gene expression in the amygdala of rats during early withdrawal from 
chronic cocaine administration and following betaxolol treatment. Lastly, implicit to our 
hypothesis is the localization of β1-adrenergic receptor to amygdalar CRF-containing 
neurons, which has not heretofore been reported. Sections through the forebrain of male 
Sprague Dawley rats were processed for the dual immunocytochemical detection of β1-
adrenergic receptor and CRF using confocal fluorescence and electron microscopy.
Materials and Methods
Animal Use and Care
Adult male Sprague Dawley rats (Harlan, Indianapolis, IN; age ≥ 60 days old, 250–274 g) 
were used in this study. The animal procedures used were approved by the Institutional 
Animal Care and Use Committee at Thomas Jefferson University and conform to National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. Rats were housed 
two per cage on a 12-h light schedule (lights on at 7:00 am) in a temperature-controlled 
(20°C) colony room and allowed ad libitum access to food and water. Rats were allowed to 
acclimate to the facility for 7 days prior to the start of the study. All efforts were made to 
minimize animal pain and suffering and reduce the number of animals used in these studies.
Drug Treatment
Cocaine hydrochloride (supplied by the National Institute on Drug Abuse, Bethesda, MD) 
was dissolved in 0.9% sodium chloride (saline) solution at a concentration of 20 mg/ml. For 
the two day withdrawal experiments, animals were randomly assigned to two treatment 
groups at the beginning of the study. One half of the animals were administered cocaine 
once daily at a dosage of 20 mg/kg via intraperitoneal (i.p.) injection for 14 days, while the 
other half of the animals received once daily i.p. injections of saline solution (1 ml/kg) for 
14 days. Subsequent to the 14 day drug administration period, animals were randomly sorted 
into the four distinct treatment groups based on the treatment they would receive during the 
48 hour withdrawal period. The four treatment groups are described in Table 1. The 48-hour 
time period following cessation of chronic cocaine administration has been shown in 
previous studies to be the point when cocaine withdrawal-related anxiety is at its peak 
(Harris and Aston-Jones, 1993; Sarnyai et al, 1995).
As indicated in Table 1, two groups of animals received betaxolol hydrochloride (Sigma, St. 
Louis, MO) dissolved in 0.9 % sodium chloride (5 mg/ml) and two groups received only 
saline (1 ml/kg) via i.p. injection during the withdrawal period. The first dose of betaxolol 
was administered 24 hours after the final treatment of chronic cocaine or saline. Another 
dose of betaxolol was administered at 44 hours following cessation of chronic cocaine 
administration. Animals were euthanized at the 48 time-point for the purposes of Western 
blot analysis and/or qRT-PCR experiments. The dose of betaxolol administered (5 mg/kg) 
was chosen based on dose response studies from our laboratory. This specific dose used in 
the present study has been shown to be effective in ameliorating cocaine withdrawal-
induced anxiety-like behavior in animals (Rudoy and Van Bockstaele, 2006).
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Protein Extraction
Animals were briefly exposed to isoflurane and then euthanized by decapitation. Brain tissue 
was rapidly removed on ice from each animal and using a trephine and razor blades, the 
amygdala brain region (approximately 0.02 g wet weight) was micro-dissected from each 
(see Supplemental Figure 1). The amygdala was homogenized with a pestle and extracted in 
RadioImmunoPrecipitation Assay (RIPA) lysis buffer (Santa Cruz Biotechnology, Santa 
Cruz, CA) on ice for 20 min. Lysates were cleared by centrifugation at 13,000 rpm for 12 
min at 4 °C.
Nuclear and Cytoplasmic Protein Extraction
Animals were briefly exposed to isoflurane and then euthanized by decapitation. Brain tissue 
was rapidly removed on ice from each animal and using a trephine and razor blades, the 
amygdala brain region (approximately 0.02 g wet weight) was micro-dissected from each. 
Lysates containing the nuclear and cytoplasmic protein fractions of each sample were 
prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagent kit (Pierce, 
Rockford, IL) according to manufacturer’s instructions.
Western Blotting
Supernatants or protein extracts were diluted with an equal volume of Novex® 2X Tris-
Glycine Sodium Dodecyl Sulfate (SDS) sample buffer (Invitrogen, Carlsbad, CA) 
containing dithiothreitol (DTT; Sigma). Protein concentrations of the undiluted supernatants 
were quantified using the bicinchoninic acid (BCA) protein assay reagent (Pierce, Rockford, 
IL). Cell lysates containing equal amounts of protein were separated on 4–12% Tris-Glycine 
polyacrylamide gels. Whole (un-fractionated) extracts, cytoplasmic extracts and nuclear 
extracts were loaded onto separate gels at 20 μg, 15 μg and 5 μg per lane, respectively. Next, 
gels were electrophoretically transferred to Immobilon-P PVDF membranes (Millipore, 
Bedford, MA). Membranes were incubated in PKA regulatory subunit (1.5 μg/ml; Upstate 
Cell Signaling Solutions, Lake Placid, NY), PKA catalytic subunits (1 μg/ml, Abcam Inc., 
Cambridge, MA), pCREB (1:1000; Cell Signaling Technology, Danvers, MA), CREB (2.5 
μg/ml; Abcam Inc.) or TATA binding protein (1:2000; Abcam Inc.) primary antibodies (a 
minimum of two hours) and then alkaline phosphatase conjugated secondary antibodies for 
30 minutes in order to probe for the presence of proteins using a Western blotting detection 
system (Western Breeze Chemiluminescent Kit, Invitrogen). Following incubation in a 
chemiluminescent substrate (Western Breeze Chemiluminescent Kit, Invitrogen), blots were 
exposed to X-OMAT AR film (Kodak, Rochester, NY) for different lengths of time to 
optimize exposures. PKA regulatory subunit, PKA catalytic subunit, pCREB, CREB and 
TATA binding protein expression were readily detected by immunoblotting in rat amygdala 
extracts, and each were visualized as a single band that migrated at approximately 52, 42, 
43, 43 and 38 kDa, respectively. Blots were incubated in stripping buffer (Restore Stripping 
Buffer, Pierce) to disrupt previous antibody-antigen interactions and then re-probed with β-
actin antibody (1:5000; 1 hour incubation, Sigma) to ensure proper protein loading. The 
band densities of the western blots were quantified using Un-Scan-It blot analysis software 
(Silk Scientific Inc., Orem, Utah). PKA regulatory subunit and PKA catalytic subunit 
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immunoreactivity was normalized to β-actin immunoreactivity for each animal. pCREB 
immunoreactivity was evaluated relative to CREB immunoreactivity for each animal.
Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR)
Animals (n=6–8 per treatment group; see Table 1) were briefly exposed to isoflurane and 
then euthanized by decapitation. Brain tissue was rapidly removed on ice from each animal 
and using a trephine and razor blades, the amygdala and frontal cortex brain regions 
(approximately 0.02 g wet weight) were micro-dissected from each. Total RNA was 
extracted from these regions using the RNeasy Mini kit (Qiagen Inc., Valencia, CA) 
according to the manufacturer’s recommendations. Residual genomic DNA was digested in 
these extracts with DNA-free™ DNase Treatment (Ambion, Austin, TX) at room 
temperature for 30 min. RNA extracts were spectrophotometrically quantitated and cDNAs 
were synthesized from 2 μg of each RNA extract using oligo (dT) primer and the 
Omniscript® Reverse Transcription kit (Qiagen). Subsequently, cDNAs were stored at −20 
°C.
Primer sequences were designed for CRF to contain minimal internal structures (i.e. primer 
dimers) using the Primer Express software (Applied Biosystems, Foster City, CA). The 
primer sequences used for CRF were as follows: 5′-GGCCAGGGCAGAGCAGTT 
(forward) and 5′-GGCCAAGCGCAACATTTC (reverse). The housekeeping gene, 
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), was used as an internal control since 
this gene is constitutively expressed at high levels in most tissues. A QuantiTect Primer 
Assay was used for amplification of GAPDH (Qiagen).
Thermal cycling, SYBR Green fluorescence detection and data collection was done in a 
real-time PCR thermal cycler (ABI 7500 Sequence Detection System, Applied Biosystems). 
Each 25 ul PCR reaction consisted of 1 μl RT product, 1 μM each of forward and reverse 
CRF primers or 10X GAPDH primer assay (according to manufacturer’s instructions) and 
12.5 μl SYBR Green (Applied Biosystems). Thermal cycling conditions were 10 min at 95 
°C, followed by 40 cycles of 30 s at 95 °C, 30 s at 55 °C and 30 s at 72 °C. A dissociation 
analysis was performed after the final PCR cycle to verify that nonspecific PCR products 
were not generated during the PCR run. Additionally, validation experiments using dilutions 
of untreated sample verified that amplification efficiencies of both CRF and the 
housekeeping gene were approximately equal.
Data collected by the ABI 7500 Sequence Detection System was expressed as a function of 
threshold cycle (CT), which represents the PCR cycle at which an increase in SYBR Green 
fluorescence above a base line signal can be first detected. Relative quantitative gene 
expression was calculated with the 2−ΔΔCT method described in Livak and Schmittgen, 2001 
(Livak and Schmittgen, 2001). For each sample, the CT for reactions amplifying the gene of 
interest and the housekeeping gene were determined. The CT value of CRF for each sample 
was normalized by subtracting the CT value of GAPDH (ΔCT). Saline controls were used as 
reference samples with mean ΔCT for the control sample being subtracted from the ΔCT for 
all of the other experimental samples (ΔΔCT). Lastly, CRF mRNA abundance in 
experimental groups was calculated relative to CRF mRNA abundance in control samples 
using the formula 2−ΔΔCT.
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Statistical Analysis
Statistical analysis of the Western blotting data was performed on the normalized 
densitometry values using one-way ANOVA followed by post-hoc Newman-Keuls Multiple 
Comparison test. For the qRT-PCR data, average differences in cycle thresholds were 
analyzed between treatment groups using one-way ANOVA followed by post-hoc Newman-
Keuls Multiple Comparison test. Significance for all statistical tests was set at p<0.05.
Immunofluorescent Histochemistry and Confocal Microscopy
Animals (n=5) were deeply anesthetized with sodium pentobarbital (60 mg/kg) and 
transcardially perfused through the ascending aorta with heparin (1000 units/ml) followed 
by 4% formaldehyde (Electron Microscopy Sciences, Hatfield, PA) in 0.1 M phosphate 
buffer (PB, pH 7.4) (Van Bockstaele et al, 1989). The brains were extracted, and 40 μm-
thick coronal sections were cut through the rostrocaudal extent of the amygdala (Paxinos 
and Watson, 1986) using a Vibratome (Technical Product International, St. Louis, MO) and 
collected into chilled 0.1 M PB.
Tissue sections of the amygdala were incubated in 1% sodium borohydride solution for 30 
min to remove reactive aldehydes. They were rinsed in 0.1 M PB and 0.1 M tris–saline 
buffer (TS; pH 7.6). Sections were then blocked in 0.5% bovine serum albumin (BSA) in 0.1 
M TS for 30 min and rinsed extensively in 0.1 M TS. Tissue sections were incubated in a 
cocktail of rabbit anti-β1-adrenergic receptor (1:1000; Oncogene Science, Cambridge, MA) 
and guinea pig anti-CRF (1:2000; Peninsula Laboratories, Inc., San Carlos, CA) primary 
antibodies made in 0.1 M TS containing 0.1% BSA at room temperature overnight on a 
rotary shaker. Subsequently, tissue sections were rinsed in 0.1 M TS and then incubated in a 
cocktail of fluorescein isothiocyanate donkey anti-rabbit (1:100; Jackson Immunoresearch 
Laboratories, Inc., West Grove, PA) and rhodamine isothiocyanate donkey anti-guinea pig 
(1:100; Jackson Immunoresearch Laboratories, Inc.) secondary antibodies made in 0.1 M TS 
containing 0.1% BSA (3 hrs). Lastly, tissue sections were rinsed in 0.1 M TS and mounted 
onto gelatinized slides. The sections were air-dried in an enclosure protected from light. 
Once dry, the slides were dehydrated in a series of alcohols, ending in xylene and 
coverslipped using DPX (Sigma-Aldrich, St. Louis, MO).
Immunofluorescence labeling was analyzed on the sections using a Zeiss LSM 510 Meta 
confocal microscope (Oberkochen, Germany). Images of fluorescent labeling of the sections 
were captured and dual fluorescence merged images were generated by the confocal 
microscope.
Immunoelectron Microscopy and Electron Microscopy
Rats (n=5) were deeply anesthetized with sodium pentobarbital (60 mg/kg) and perfused 
transcardially through the ascending aorta with 10 ml heparinized saline followed by 50 ml 
of 3.75% acrolein (Electron Microscopy Sciences), and 200 ml of 2% formaldehyde 
(Electron Microscopy Sciences) in 0.1 M PB (pH 7.4). The brains were immediately 
removed and sectioned into 1–3 mm coronal slices. The slices were post-fixed for 30 min 
and 40 μm-thick sections were cut through the rostrocaudal extent of the amygdala using a 
Vibratome and collected into chilled 0.1 M PB. Forty-μm thick sections through the 
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rostrocaudal extent of the amygdala were processed for electron microscopic analysis of β1-
adrenergic receptor and CRF in the same sections and were processed following the same 
protocol described above for immunofluorescent histochemistry until the point of the 
secondary antibody incubation.
Tissue sections were incubated in a primary antibody cocktail of rabbit anti-β1-adrenergic 
receptor (1:1000; Oncogene Science, Cambridge, MA) and guinea pig anti-CRF (1:2000; 
Peninsula Laboratories, Inc.) for 15–18 h at room temperature. The following day, tissue 
sections were rinsed three times in 0.1 M TS, incubated in biotinylated donkey anti-rabbit 
(1:400; Jackson Immunoresearch Laboratories, Inc.) and biotinylated donkey anti-guinea pig 
(1:400; Jackson Immunoresearch Laboratories, Inc.) for 30 min, and then rinsed again in 0.1 
M TS. Next, sections underwent a 30 min incubation in an avidin-biotin complex (Vector 
Laboratories, Burlingame, CA). CRF immunoreactivity was visualized by a 6 min reaction 
in 22 mg of 3,3′-diaminobenzidine (Sigma-Aldrich Inc., St. Louis, MO) and 10 μl of 30% 
hydrogen peroxide in 100 ml of 0.1 M TS. Sections were continuously agitated with a rotary 
shaker during all aforementioned incubations and washes.
For gold-silver localization of β1-adrenergic receptor, sections were rinsed three times with 
0.1 M TS, followed by rinses with 0.1 M PB and 0.01 M phosphate buffered saline (PBS; 
pH 7.4). Sections were then incubated in a 0.2% gelatin-PBS and 0.8% BSA buffer for 10 
min. Subsequently, sections were incubated in 1nm gold anti-rabbit antibody (1:50; 
Amersham Biosciences, Piscataway, NJ, USA) at room temperature for 2 hours. Next, 
sections were rinsed in 0.2% gelatin-PBS and 0.8% BSA buffer and followed by a rinse in 
0.01 M PBS. Sections were then incubated in 2% glutaraldehyde (Electron Microscopy 
Sciences) in 0.01 M PBS for 10 min followed by washes in 0.01 M PBS and 0.2 M sodium 
citrate buffer (pH 7.4). A silver enhancement kit (Amersham Biosciences) was used for 
silver intensification of the gold particles. The optimal times for silver enhancement time 
were determined by empirical observation but ranged from 12–15 min. Following silver 
intensification, tissue sections were rinsed in 0.2 M citrate buffer and 0.1 M PB, incubated in 
2% osmium tetroxide (Electron Microscopy Sciences) in 0.1 M PB for 1 h, washed in 0.1 M 
PB, dehydrated in an ascending series of ethanol followed by propylene oxide and flat 
embedded in Epon 812 (Electron Microscopy Sciences) (Leranth and Pickel, 1989; Van 
Bockstaele and Pickel, 1993).
Flat embedded tissue sections were mounted onto Epon capsules and thin sections 
approximately 50–100 nm in thickness were cut with a diamond knife (Diatome-US, Fort 
Washington, PA, USA) using a Leica Ultracut (Leica Microsystems, Wetzlar, Germany). 
Sections were collected on copper mesh grids and examined with a Hitachi electron 
microscope. Digital electron micrographic images were collected and figures were 
assembled using Adobe Photoshop.
The cellular elements (cell bodies, dendrites, axon terminals) were identified based on the 
description of Peters and colleagues (Peters et al, 1991). A terminal was considered to form 
a synapse if it showed synaptic vesicles near a restricted zone of parallel membranes with 
slight enlargement of the intercellular space, and/or associated with postsynaptic thickening. 
Asymmetric synapses were identified by thick postsynaptic densities (Gray’s type I) (Gray, 
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1959), in contrast, symmetric synapses had thin densities (Gray’s type II) (Gray, 1959) both 
pre-and postsynaptically. A non-synaptic apposition was defined as an axon terminal plasma 
membrane juxtaposed to that of a dendrite or soma devoid of recognizable membrane 
specializations and no intervening glial processes.
Results
Betaxolol blocks cocaine withdrawal-induced increases in amygdalar PKA regulatory 
subunit expression
A one-way ANOVA analysis demonstrated a significant difference among treatment groups 
(see Table 1; n=5/treatment group) in PKA regulatory subunit expression by western blot 
analysis [p=0.0284, F(3,16)=3.916] and post-hoc comparison tests among these groups 
revealed the differences. In Figure 1, amygdalar PKA regulatory subunit immunoreactivity 
of the groups of animals is expressed as a percentage of the control mean when the control 
equals 100 (±S.E.M.). Amygdala extracts from animals undergoing cocaine withdrawal with 
no betaxolol treatment (CS) exhibited a significant increase (p<0.05) in PKA regulatory 
subunit protein expression compared to saline control animals (SS). Likewise, PKA 
regulatory subunit immunoreactivity was significantly greater (p<0.05) in cocaine 
withdrawn animals (CS) compared to animals treated with chronic saline followed by 
betaxolol treatment (SB). However, there was no significant difference (p>0.05) in PKA 
regulatory subunit protein expression levels between animals treated with chronic saline and 
no betaxolol (SS) and animals treated with chronic saline followed by betaxolol treatment 
(SB). Betaxolol administration had a significant effect on PKA regulatory subunit 
expression in the amygdala of animals that underwent cocaine withdrawal (CB), as 
amygdala extracts from those animals displayed a significant decrease (p<0.05) in PKA 
regulatory subunit expression compared to cocaine administered animals that did not receive 
betaxolol treatment during withdrawal (CS). Also of importance, amygdala extracts from 
animals treated with betaxolol during cocaine withdrawal (CB) exhibited similar levels of 
PKA regulatory subunit protein expression as animals treated with chronic saline and no 
betaxolol treatment (SS; p>0.05), and also animals treated with chronic saline followed by 
betaxolol treatment (SB; p>0.05). Statistical significance is indicated on graph; * p<0.05 
(Figure 1).
Betaxolol reverses cocaine withdrawal-induced alterations in PKA catalytic subunit 
expression in amygdalar cytoplasmic and nuclear extracts
By ANOVA analysis, there was a significant difference among treatment groups (see Table 
1; n=5/treatment group) in PKA catalytic subunit expression in both cytoplasmic [p=0.0085; 
F(3,16)=5.523] and nuclear [p=0.0166; F(3,16)=4.601] amygdalar extracts. PKA catalytic 
subunit immunoreactivity in both the cytoplasmic and nuclear amygdalar extracts was 
plotted as a percentage of the control mean when the control equals 100 (±S.E.M.; Figure 2). 
Amygdala cytoplasmic extracts from animals undergoing cocaine withdrawal with no 
betaxolol treatment (CS) exhibited a significant decrease (p<0.05) in PKA catalytic subunit 
protein expression compared to saline control animals (SS; bottom left). Alternatively, PKA 
catalytic subunit expression was significantly elevated (p<0.05) in nuclear extracts from CS 
animals compared to controls (SS; bottom right), indicating the likely translocation of PKA 
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catalytic subunit from the cytoplasm to the nuclear compartment during early cocaine 
withdrawal. Cytoplasmic and nuclear amygdalar extracts from animals receiving betaxolol 
administration during cocaine withdrawal (CB; both left and right bottom) demonstrated a 
reversal of these alterations in PKA catalytic subunit protein levels. Hence, following 
betaxolol treatment (CB), PKA catalytic subunit expression was returned to levels 
comparable to those of control animals (SS) in both cytoplasmic and nuclear amygdalar 
extracts. Statistical significance between groups of animals is indicated on graphs; * p<0.05, 
** p<0.01 (Figure 2).
Critical to the significance of the alterations in expression of PKA catalytic subunit that we 
demonstrated in these studies was the precision of the nuclear and cytoplasmic extraction 
procedure. In order to confirm that our extracts contained only the nuclear or cytoplasmic 
cellular fractions as desired, we probed blots containing these extracts with an antibody 
targeted towards TATA Binding protein. TATA Binding protein is a DNA binding protein 
that binds specifically to the TATA box found in gene promoters, and is vital to the 
initiation of all eukaryotic transcription (Moore et al, 1999). Hence, TATA Binding protein 
makes a useful loading control for nuclear extracts (Kwintkiewicz et al, 2007). TATA 
Binding protein immunoreactivity was detected in nuclear extracts from all treatment groups 
(Figure 2).
Betaxolol blocks cocaine withdrawal-induced increases in CREB phosphorylation in 
amygdalar nuclear extracts
A significant difference was found between groups (see Table 1, n=5/treatment group) in 
CREB phosphorylation in amygdalar nuclear extracts [p=0.0354, F(3,16)=3.650]. pCREB 
protein densitometry levels were evaluated relative to CREB densitometry levels for each 
animal. pCREB/CREB immunoreactivity in the amygdala of these animals was plotted as a 
percentage of the control mean when the control equals 100 (±S.E.M.; Figure 3). Amygdala 
extracts from animals undergoing cocaine withdrawal with no betaxolol treatment (CS) 
exhibited a significant increase (p<0.05) in CREB phosphorylation compared to saline 
control animals (SS). Likewise, pCREB immunoreactivity was significantly greater (p<0.05) 
in cocaine withdrawn animals (CS) compared to animals treated with chronic saline 
followed by betaxolol treatment (SB). There was no significant difference (p>0.05) in 
pCREB protein levels between animals treated with chronic saline and no betaxolol (SS) and 
animals treated with chronic saline followed by betaxolol treatment (SB). Amygdala extracts 
from animals that were administered betaxolol during cocaine withdrawal (CB) displayed a 
significant decrease (p<0.05) in CREB phosphorylation compared to cocaine administered 
animals that did not receive betaxolol treatment during withdrawal (CS). Amygdala extracts 
from CB animals exhibited similar levels of pCREB protein as saline control animals (SS; 
p>0.05), and also animals treated with chronic saline followed by betaxolol treatment (SB; 
p>0.05).
TATA binding protein (BP) immunoreactivity was used as a nuclear loading control in these 
experiments. Cytoplasmic extracts lack immunoreactivity for TATA BP, while nuclear 
extracts demonstrate TATA BP immunoreactivity (Figure 3).
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Betaxolol attenuates cocaine withdrawal-induced increases in amygdalar CRF mRNA 
levels
Data from the RT-PCR experiments was analyzed by the comparative CT method using the 
formula 2−ΔΔCT. Fold change differences in CRF mRNA abundance in the three drug 
treatment groups (CS, SB and CB; see Table 1) were plotted relative to saline control (SS) 
when the saline control group equals 1 (Figure 4). Comparison of average threshold cycles 
for CRF between the treatment groups using one-way ANOVA revealed a significant 
difference in CRF mRNA expression between the groups [see Table 1; p=0.0156, 
F(3,22)=4.306] and post-hoc Newman-Keuls Multiple Comparison test detailed these 
differences. Confirming reports of others (Zhou et al, 2003), our data demonstrated that 
CRF mRNA expression was significantly upregulated in amygdalar extracts from animals 
following early cocaine withdrawal (Figure 4, CS vs. SS; p<0.05). However, this increase 
was blocked in amygdalar extracts from animals that were treated with betaxolol following 
cocaine administration (CB vs. CS, p<0.05). Betaxolol treatment alone did not have any 
significant effect on amygdalar CRF mRNA expression (SB vs. SS; p>0.05). Using qRT-
PCR, we also examined CRF mRNA expression levels in frontal cortex micro-dissections 
that we extracted from animals from the four drug treatment groups (see Table 1). From 
these experiments, we found no statistically significant difference in CRF mRNA expression 
levels in frontal cortex extracts among these groups (data not shown). Collectively, the 
Western blotting and qRT-PCR data from the present study suggest that betaxolol treatment 
during cocaine withdrawal may block increases in amygdalar CRF gene expression by 
attenuating an amygdalar β1-adrenergic receptor-mediated cell signaling pathway (see 
Figure 5).
β1-adrenergic receptors are located on numerous CRF-containing neurons of the CNA
β1-adrenergic receptors were frequently observed on CRF-containing neurons of the central 
nucleus of the amygdala (CNA) and this observation was made using both confocal and 
electron microscopy. For immunofluorescent confocal microscopy, rat brain tissue sections 
containing the amygdala were labeled for CRF using rhodamine isothiocyanate-conjugated 
secondary antibody, while β1-adrenergic receptors were labeled using fluorescein 
isothiocyanate-conjugated secondary antibody. Using confocal microscopy, CRF 
immunoreactivity was characterized as a diffuse red fluorescent product and was localized 
to cell bodies (Figure 6, A and D; thick white arrows), whereas β1-adrenergic receptor 
immunoreactivity was visualized as a punctate green fluorescent label also localized to 
perikarya (Figure 6, B and E; thick white arrows). When the fluorescent images were 
merged, dual labeling for both CRF and β1-adrenergic receptor was identified as a yellow 
fluorescent label (Figure 6, C and F; thick white arrows). Not all CRF-labeled cells in the 
CNA contained labeling for β1-adrenergic receptor (Figure 6, A, C, D and F; thin white 
arrows) and we also observed some β1-adrenergic receptor labeling not on CRF neurons.
Using electron microscopy, we observed ultrastructural evidence for co-localization of β1-
adrenergic receptors and CRF in the amygdala. CRF immunoreactivity was identified by an 
electron-dense peroxidase reaction product and β1-adrenergic receptor immunoreactivity 
was visualized as immunogold-silver particles. A profile was considered to be positive for 
immunogold particle labeling only if three or more immunogold particles were present in the 
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same profile. CRF and β1-adrenergic receptor immunoreactivities were sometimes observed 
in separate dendrites in the same neuropil (Figure 7, A), but were often observed co-
localized in the same dendrites of the CNA (Figure 7, B and C). We quantified the 
frequency of co-localization and found that of the profiles exhibiting immunoreactivity for 
β1-adrenergic receptor (n=474), 45% of these profiles also contained CRF labeling. 
Furthermore, of the profiles exhibiting CRF immunoreactivity (n=389), 55% of these 
profiles also contained β1-adrenergic receptor immunoreactivity. We also observed that 
dendrites of co-localized CRF and β1-adrenergic receptors form both asymmetric (curved 
arrows) and symmetric (double arrows) synapses with axon terminals (Figure 7, B and C).
By electron microcopy, we also investigated the distribution of β1-adrenergic receptors in 
CRF-immunoreactive dendritic processes in the amygdala. β1-Adrenergic receptors were 
found located within the cytoplasmic compartment and also distributed along the plasma 
membrane of CRF-immunoreactive dendrites (Figure 8). We quantified the frequency of 
localization of β1-adrenergic receptor labeling either on the plasma membrane versus within 
the cytoplasm of CRF-labeled profiles and determined that 62.3% of our dual CRF and β1-
adrenergic receptor -labeled profiles exhibited β1-adrenergic receptor labeling on the plasma 
membrane, while 37.7% of these profiles demonstrated β1-adrenergic receptor labeling 
within the cytoplasm.
Discussion
Our previous studies demonstrated increased amygdalar β1-adrenergic receptor expression 
during early cocaine withdrawal (Rudoy and Van Bockstaele, 2006). The present study 
extends these previous results by showing that alterations in amygdalar cell signaling and 
amygdalar CRF gene expression accompany these alterations. We further demonstrate that 
treatment with betaxolol, a selective β1-adrenergic receptor antagonist (Mosby, 2006), 
during early cocaine withdrawal (2 days) blocks increases in a β1-adrenergic receptor-
mediated cell signaling pathway and CRF gene expression. These data suggest a potential 
cellular mechanism underlying the efficacy of betaxolol in the treatment of cocaine 
withdrawal. These findings could have important implications in the pursuit of potential 
pharmacotherapies for the treatment of withdrawal-induced anxiety following cocaine 
addiction.
Early periods of withdrawal from chronic cocaine administration are accompanied by 
significant anxiety-like behavior (Harris and Aston-Jones, 1993; Sarnyai et al, 1995; Rudoy 
and Van Bockstaele, 2006). This behavior has been attributed, in part, to increases in both 
amygdalar CRF gene expression (Sarnyai et al, 1995; Zhou et al, 2003) and β1-adrenergic 
receptor expression (Rudoy and Van Bockstaele, 2006). The hypothesis that β1-adrenergic 
receptors localized to amygdalar CRF neurons play an important role in withdrawal-induced 
anxiety is emerging as it has already been established that norepinephrine and CRF systems 
interact in the brain to modulate stress responses (Valentino et al, 1991; Valentino et al, 
1993; Li et al, 1998; Koob, 1999; Van Bockstaele et al, 1999).
Activation of β1-adrenergic receptors stimulates Gs, and this, in turn, results in an increase in 
intracellular cAMP levels (Schultz and Daly, 1973) (see Figure 5). Accumulation of 
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intracellular cAMP (Montminy, 1997) results in PKA activation, whereby, the binding of 
cAMP causes PKA regulatory subunits to alter their conformation, and the catalytic subunits 
to dissociate from the complex (Gonzalez and Montminy, 1989; Gonzalez et al, 1991; 
Alberts et al, 2002). The catalytic subunits translocate into the nucleus to phosphorylate 
specific substrate protein molecules, such as CREB, while the regulatory subunits remain in 
the cytoplasm (Gonzalez and Montminy, 1989; Gonzalez et al, 1991; Siegal et al, 1999; 
Purves et al, 2001; Alberts et al, 2002).
Our results showing an increase in PKA catalytic subunit expression in nuclear amygdalar 
extracts and a simultaneous decrease in PKA catalytic subunit expression in cytoplasmic 
amygdalar extracts from rats following cocaine withdrawal suggest a translocation of the 
PKA catalytic subunits to the nucleus. This translocation indicates PKA activation (Asyyed 
et al, 2006). Interestingly, the expression of PKA regulatory subunit was significantly 
increased in whole amygdalar extracts during this time period also. The alteration in PKA 
we observed was accompanied by a significant increase in CREB phosphorylation in 
amygdalar nuclear extracts, while overall CREB levels remained unchanged. Our finding 
demonstrating increases in CREB phosphorylation further supports activated PKA in our 
cocaine withdrawn animals, as phosphorylation of CREB at Ser-133 occurs in response to 
PKA activation (Montminy, 1997; Mayr and Montminy, 2001; Johannessen et al, 2004).
Activation of PKA within the amygdala is thought to contribute to the synaptic plasticity 
and reward-related learning that underlies pathologic behavior in drug addicted individuals 
(Robbins and Everitt, 1999; Berke and Hyman, 2000; Jentsch et al, 2002). Jentsch et al. 
demonstrated that intra-amygdalar infusions of Sp-cAMP, which activates PKA, in rats 
produces concentration-dependent enhancements of the acquisition of approach to a 
conditioned stimulus that predicts water availability (Jentsch et al, 2002). A similar effect 
was produced in animals using intra-amygdalar infusion of cholera toxin, which elevates 
cAMP levels. On the contrary, intra-amygdalar infusions of Rp-cAMPS, an inhibitor of 
PKA, impaired acquisition of approach behavior (Jentsch et al, 2002). Modulation of PKA 
activation in other brain regions, such as the nucleus accumbens, has also been specifically 
associated with cocaine self-administration (Self et al, 1998) and motivation to obtain 
cocaine (Lynch and Taylor, 2005). In rats self administering cocaine under a fixed ratio 1 
schedule (each response produces an infusion of cocaine), activation of PKA in the nucleus 
accumbens produced increases in levels of cocaine intake whereas, inhibition produced a 
decrease in total intake (Self et al, 1998). After extinction from cocaine self-administration, 
infusions of Sp-cAMPS into the nucleus accumbens induced generalized responding at both 
drug-paired and inactive levers and increased phosphorylation of CREB (Self et al, 1998). In 
another study, bilateral infusions of Sp-cAMPS resulted in an increase in progressive ratio 
responding for cocaine, whereas infusions of Rp-cAMPS produced persistent decreases in 
progressive-ratio responding (Lynch and Taylor, 2005).
Data from the aforementioned studies suggest that PKA activation may be involved in the 
incentive and motivational aspects of drug addiction, which could contribute to compulsive 
drug seeking behavior (Robinson and Berridge, 1993; Robbins and Everitt, 1999; Jentsch et 
al, 2002). It is plausible then that the activation of PKA that we observed in the amygdala 
during early cocaine abstinence may have multiple consequences. Our data add to this 
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growing literature and suggests that this activation may serve as a molecular substrate for 
the cocaine withdrawal-related anxiety that occurs during this time period. This conjecture is 
supported by observation of a concomitant significant increase in amygdalar CRF gene 
expression during early withdrawal, a result previously described by others (Zhou et al, 
2003), but whose mechanism was unknown. Therefore, it is tempting to speculate that the 
alterations in cell signaling that we observed during this time period contribute to increased 
CRF gene expression.
Elevations in CREB phosphorylation have also been observed in the brain after exposure to 
various stressors, including forced-swim and restraint stress (Kreibich and Blendy, 2005) 
and are thought to be involved in cocaine-induced drug reinstatement (Kreibich and Blendy, 
2004). PKA, pCREB and cAMP-dependent CRE-mediated transcription have also been 
specifically implicated in alcoholism (Thiele et al, 2000; Pandey et al, 2001; Pandey et al, 
2005). Alcohol-preferring rats, which exhibit increased ethanol consumption, express lower 
levels of CREB and pCREB in the CNA and medial amygdala (MeA), but not in the 
basolateral nucleus of the amygdala (BLA) compared to non-preferring rats (Pandey et al, 
2005). It is thought that these alcohol-preferring rats voluntarily drink excessive amounts of 
alcohol to reduce high anxiety levels that occur in these animals during this time (Pandey et 
al, 2005). This concept is further supported by evidence demonstrating that ethanol intake 
reduced higher anxiety levels in alcohol-preferring rats and also increased CREB function in 
these animals (Pandey et al, 2005). More recent studies have shown that ethanol withdrawal-
induced anxiety in rats is accompanied by decreased CREB phosphorylation, as well as 
decreased activation of other cell signaling elements, in the CNA and MeA, but not in the 
BLA (Pandey et al, 2008).
The findings of the aforementioned alcohol studies are contrary to our studies that 
demonstrate increased expression of anxiety-like behavior in animals during cocaine 
withdrawal (Rudoy and Van Bockstaele, 2006) coincident with increased CREB 
phosphorylation in the amygdala. However, while the immunofluorescent and electron 
microscopy experiments were focused largely on evaluating β1-adrenergic receptor 
immunoreactivity in relation to CRF immunoreactivity in the CNA, a limitation of our 
present study is that the Western blotting and RT-PCR experiments were performed on 
amygdalar extracts containing the CNA, as well as, other nuclei of the amygdala. Given the 
cellular alterations that we have observed in the whole amygdala micro-dissections, and the 
divergent alterations in CREB activation that we have observed compared to previous 
studies in alcohol addiction, future experiments will be aimed at evaluating potential 
alterations in CREB activation in the individual amygdalar nuclei. However, we speculate 
that the cellular changes we observed in the present study are likely a reflection of changes 
occurring in the CRF-rich CNA specifically since previous studies demonstrate that the 
CNA is implicated in mediating cocaine withdrawal symptomatology, such as anxiety (Maj 
et al, 2003; Zhou et al, 2003), and is also associated with mediating stress-induced 
reinstatement of cocaine seeking in rats (Erb et al, 2001; Leri et al, 2002; McFarland et al, 
2004). Nevertheless, chronic cocaine self-administration upregulates norepinephrine 
transporter in the BLA in animals (Beveridge et al, 2005) and so, it is also plausible that 
regions such as the BLA underlie the noradrenergic receptor-mediated cellular alterations 
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that we observed. Furthermore, the BLA, thought to be fundamental in the formation and 
preservation of emotional memories, has been implicated in mediating cue-induced relapse 
to both major drugs of abuse, such as cocaine (Fuchs and See, 2002; See, 2005) and heroin 
(Hellemans et al, 2006).
Our findings showing increased CREB phosphorylation during early phases of withdrawal 
are interesting in light of previous studies that have demonstrated an association between 
increased pCREB and increased CRF gene activation (Kovacs and Sawchenko, 1996a; 
Kovacs and Sawchenko, 1996b; Yao et al, 2007). When CREB is phosphorylated, it 
functions to stimulate transcription in genes that contain the cAMP response element (CRE) 
in their promoter regions (Siegal et al, 1999; Mayr and Montminy, 2001). It has been 
established that the CRF gene contains a CRE element in the promoter region and CRF gene 
transcription is regulated by changes in both cAMP concentration and CRE binding 
(Seasholtz et al, 1988; Itoi et al, 1996; Hatalski and Baram, 1997). Although indirect, our 
data suggest a potentially upregulated signaling pathway that may culminate in increased 
CRF gene transcription leading to the behavioral manifestation of anxiety.
In the present study, we demonstrate that treatment with betaxolol during early cocaine 
withdrawal reverses the alterations in intracellular messenger expression (PKA regulatory 
subunit, PKA catalytic subunit and pCREB) that accompany elevations in β1-adrenergic 
receptors during this time period, as well as returned CRF mRNA levels to that of control 
animals. Activation of CRF neurotransmission in the amygdala is thought to mediate the 
anxiety and stress-like symptoms that characterize drug withdrawal syndromes (Sarnyai et 
al, 1995; Sarnyai, 1998; Koob, 1999; Pollandt et al, 2006). This effect may be mediated by 
not only local CRF signaling within the amygdala, but also by the activation of CRF 
projections to other brain regions which mediate anxiety and stress such as, the bed nucleus 
of the stria terminalis (Koob, 1999; Koob and Heinrichs, 1999; Bourgeais et al, 2001) and 
the noradrenergic locus coeruleus (Koob and Heinrichs, 1999; Van Bockstaele et al, 1999; 
Dunn et al, 2004).
The proposed mechanism underlying the efficacy of betaxolol treatment is supported by our 
anatomical data showing localization of β1-adrenergic receptors to CRF-containing neurons 
in the amygdala. Our anatomical studies indicate that β1-adrenergic receptors are frequently 
localized to amygdalar cells containing CRF, in that, more than half of CRF-labeled neurons 
in the amygdala also express labeling for β1-adrenergic receptor. While our experiments 
demonstrated that β1-adrenergic receptors were distributed both on the plasma membrane 
and/or in the cytoplasm of CRF-labeled neurons, we found β1-adrenergic receptors to be 
primarily localized to the plasma membrane of those neurons. This finding suggests that the 
majority of β1-adrenergic receptors on CRF neurons may be available for ligand binding, 
and hence, emphasizes the potential importance of this anatomical substrate in the 
modulation of CRF gene expression by modulation of β1-adrenergic receptors. Moreover, 
dendrites of co-localized CRF and β1-adrenergic receptors form both asymmetric and 
symmetric synapses with axon terminals, an indication that these synapses may be either 
excitatory or inhibitory in nature. Together, this compelling data further supports the 
hypothesis that the cellular interactions between β1-adrenergic receptors and CRF in the 
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amygdala may serve as an important circuit involved in the induction of anxiety following 
cessation of chronic cocaine use.
Studies from our laboratory and others have shown that early cocaine withdrawal in rats is 
characterized by the behavioral manifestation of anxiety (Rudoy and Van Bockstaele, 2006) 
and also by the augmentation of amygdalar CRF gene expression (Zhou et al, 2003). Our 
data support that these effects are likely linked to increases in amygdalar β1-adrenergic 
receptor expression that occurs during this time period. Nonetheless, it has not yet been 
determined whether treatment with a β1-adrenergic receptor agonist can mimic the effects of 
cocaine withdrawal, either by the precipitation of anxiety-like behavior or by elevating CRF 
gene expression. Hence, this type of study may indeed be a fruitful avenue to pursue in order 
to further elucidate the cellular mechanism underlying the role of β1-adrenergic receptors in 
cocaine withdrawal-related anxiety.
In conclusion, the findings contained in the present study may have pharmacotherapeutic 
implications, as blocking amygdalar β1-adrenergic receptors may be a clinically effective 
means of modulating the activation of CRF neuronal mechanisms that likely prompt 
negative symptomatology during early phases of drug withdrawal. Betaxolol is an FDA 
approved drug (brand name: Kerlone) currently used in clinical settings to treat glaucoma 
(Hardman et al, 2001; Mosby, 2006), hypertension (Mann and Gerber, 2001) and specific 
coronary dysfunctions (Koh et al, 1995). Betaxolol, is classified as highly selective for β1-
adrenegic receptors (Mosby, 2006), readily crosses the blood brain barrier (Swartz, 1998), 
and has no partial agonist activity (Mosby, 2006). Other β1–adrenergic receptor antagonists 
such as, metoprolol, atenolol, esmolol, and acebutolol were considered for use in the present 
study, but were disregarded because these agents either had limited ability to penetrate the 
brain, had some intrinsic sympathomimetic activity or had a very short duration of action 
(Hardman et al, 2001).
Propranolol (brand name: Inderal), a non-selective beta-adrenergic receptor antagonist, used 
to treat hypertension, has demonstrated efficacy in blocking cocaine withdrawal-induced 
anxiety in rats during early abstinence (2 days) from chronic cocaine administration (20 
mg/kg/day, 14 days) (Harris and Aston-Jones, 1993) and, in clinical studies, has shown 
some promising effects in individuals with more severe cocaine withdrawal symptoms 
(Kampman et al, 2001). Our previous studies (Rudoy and Van Bockstaele, 2006) 
demonstrate that no significant alteration in amygdalar β2-adrenergic receptor expression 
occurs during cocaine withdrawal in rats, alas, propanolol may not be the most ideal 
treatment for cocaine withdrawal-related anxiety, as propanolol blocks both β1- and β2- 
adrenergic receptors. β2-adrenergic receptors, similar to β1-adrenergic receptors, are Gs-
protein-coupled receptors and both function to increase cAMP. However, at present, there is 
no evidence in the literature that these two receptors regulate expression of the exact same 
genes. More specifically, the present study demonstrates that treatment with betaxolol 
during cocaine withdrawal blocks increases in amygdalar CRF gene expression; an effect 
that we hypothesize may underlie its efficacy in ameliorating withdrawal-related anxiety. 
Propanolol may also potentially affect amygdalar CRF gene expression, as it blocks both β1- 
and β2-adrenergic receptors, however, it is unknown at this time if this molecular alteration 
could underlie the partial efficacy of propanolol in treating cocaine withdrawal 
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symptomatology. It is also conceivable that propanolol has not met with full success in 
treating cocaine withdrawal symptoms, since propanolol, by unnecessarily blocking β2-
adrenergic receptors that have not been altered by the drug withdrawal, could possibly elicit 
counter-productive effects (e.g. disturb the regulation of other genes). Collectively, the 
preclinical and clinical studies described above are supportive of the potential 
pharmacotherapeutic value of betaxolol in the treatment of cocaine withdrawal-related 
anxiety. However, future studies are warranted to further characterize the biological 
underpinnings of amygdalar involvement in withdrawal-induced anxiety, as well as examine 
the effect of direct intracranial β1-adrenergic receptor blockade on amygdalar CRF peptide 
expression and CRF release in this important limbic region.
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Figure 1. 
Western blots demonstrating PKA Regulatory Subunit immunoreactivity in the amygdala of 
animals from four different drug treatment groups (see Table 1). PKA Regulatory Subunit 
immunoreactivity in the amygdala of these animals is expressed as a percentage of the 
control mean when the control equals 100 (±S.E.M.). PKA regulatory subunit expression is 
elevated in the amygdala following early cocaine withdrawal, however; this effect is 
reversed following betaxolol treatment during cocaine withdrawal. Statistical significance 
between groups of animals is indicated on graph; * p<0.05.
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Figure 2. 
Western blots demonstrating PKA Catalytic Subunit and the nuclear localization marker, 
TATA Binding Protein (BP), expression in cytoplasmic (top left) and nuclear (top right) 
amygdalar extracts obtained from four different groups of drug treated animals (see Table 
1). In both the cytoplasmic and nuclear extracts, PKA Catalytic Subunit immunoreactivity in 
the amygdala of these animals is expressed as a percentage of the control mean when the 
control equals 100 (±S.E.M.). PKA catalytic subunit expression was significantly decreased 
in amygdalar cytoplasmic extracts and concurrently increased significantly in amygdalar 
nuclear extracts from animals that underwent cocaine withdrawal. Betaxolol administration 
during early cocaine withdrawal reversed alterations in PKA catalytic subunit expression in 
amygdalar cytoplasmic and nuclear extracts to control levels. Statistical significance 
between groups of animals is indicated on graphs; * p<0.05, ** p<0.01. TATA BP 
immunoreactivity was used as a nuclear loading control. Cytoplasmic extracts lack 
immunoreactivity for TATA BP, while nuclear extracts demonstrate TATA BP 
immunoreactivity. β-actin immunoreactivity was evaluated in cytoplasmic amygdalar 
extracts (top left) as a loading control.
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Figure 3. 
Western blots demonstrating pCREB, CREB, and the nuclear localization marker, TATA 
BP, immunoreactivity in the amygdala of animals from four different drug treatment groups 
(see Table 1). pCREB protein densitometry levels were evaluated relative to CREB protein 
densitometry levels for each animal. pCREB/CREB immunoreactivity in the amygdala of 
these animals is expressed as a percentage of the control mean when the control equals 100 
(±S.E.M.). CREB phosphorylation is increased in amygdalar nuclear extracts following 
early cocaine withdrawal, however; betaxolol administration during early cocaine 
withdrawal blocks this increase. Statistical significance between groups of animals is 
indicated on graph; * p<0.05.
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Figure 4. 
Effect of betaxolol treatment during cocaine withdrawal on CRF mRNA levels in the 
amygdala. Quantitative RT-PCR data was analyzed by the comparative CT method using the 
formula 2−ΔΔCT. Fold change differences in CRF mRNA abundance in the three drug 
treatment groups (CS, SB and CB; see Table 1) are plotted relative to saline control (SS) 
when the saline control group equals 1. CRF mRNA expression was significantly increased 
in amygdalar extracts from animals following early cocaine withdrawal (CS vs. SS); 
however, this increase was attenuated in amygdalar extracts from animals that were treated 
with betaxolol following cocaine administration (CB vs. CS). Betaxolol treatment alone did 
not have any significant effect on amygdalar CRF mRNA expression (SB vs. SS). Statistical 
significance between groups of animals is indicated on graph; * p<0.05.
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Figure 5. 
Proposed cell signaling pathway of noradrenergic influence on CRF transcription. 
Norepinephrine (NE) in the extracellular space binds to a G-protein coupled adrenergic 
receptor spanning the neuronal cell membrane (1). This ligand-receptor complex then 
activates the G protein, causing the alpha subunit to dissociate from the beta and gamma 
subunits (2). The activated alpha subunit of the G protein functions to activate the plasma 
membrane bound enzyme, adenylyl cyclase (3). Adenylyl cyclase synthesizes cyclic 
adenosine monophosphate (cAMP) from adenosine triphosphate (ATP) (4). cAMP binds to 
the regulatory subunits of cycle-AMP-dependent protein kinase (PKA) (5). This induces a 
conformational change causing the regulatory subunits to release the catalytic subunits, 
thereby activating the kinase activity of the catalytic subunits (6). Once the catalytic 
subunits are freed and active, they translocate into the nucleus of the cell to phosphorylate 
cAMP response element binding protein (CREB) (7). The regulatory subunits remain in the 
cytoplasm. Phosphorylated CREB (pCREB) then recruits a transcriptional co-activator 
called CREB-binding protein (CBP) (8). CBP recognizes the regulatory region of the target 
gene called the cAMP response element (CRE) and stimulates gene transcription (9). The 
culmination of this proposed cell signaling pathway is the transcription of CRF (10).
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Figure 6. 
β1-adrenergic receptors are located on CRF-containing neurons of the amygdala. A and D: 
High magnification confocal photomicrographs of two separate coronal sections through the 
CNA labeled for CRF using rhodamine isothiocyanate-conjugated secondary antibody; thin 
arrows point to CRF-immunoreactive cells, while thick arrows indicate CRF-
immunoreactive perikarya containing β1-adrenergic receptors (see panels C and F). B and E: 
The same coronal sections as shown in figures A and D, respectively, labeled for β1-
adrenergic receptors (β1-AR) using fluorescein isothiocyanate-conjugated secondary 
antibody; thick arrows indicate CRF-immunoreactive perikarya containing β1-adrenergic 
receptors (β1-AR) (see panels C and F). C and F: Merged images of panels A and B and D 
and E, respectively. Thick arrows show immunoreactivity for CRF and β1-adrenergic 
receptors, while thin arrows indicate single-labeling for CRF only.
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Figure 7. 
Ultrastructural evidence for co-localization of β1-adrenergic receptors and CRF in the 
amygdala. A: Electron photomicrograph showing a dendrite containing immunogold-silver 
labeling (arrowheads) for β1-adrenergic receptor (β1-AR). A dendrite containing peroxidase 
labeling (arrows) for CRF (CRF-d) can also be identified in the neuropil. Scale bar: 0.50 μm. 
B–C: Electron photomicrographs showing CRF (CRF-d; immunoperoxidase) and β1-
adrenergic receptors (β1-AR; immunogold) immunoreactivities co-localized in dendrites of 
the CNA. Arrowheads indicate immunogold particles for β1-adrenergic receptors (β1-AR) 
and peroxidase labeling for CRF (CRF-d; arrows) is identified as electron-dense reaction 
product. Dendrites of co-localized CRF and β1-adrenergic receptors form asymmetric 
(curved arrows) and symmetric (double arrows) synapses with axon terminals. Scale bars: 
0.50 μm. Abbreviations: m, mitochondria; ut, unlabeled terminal.
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Figure 8. 
Distribution of β1-adrenergic receptors in CRF-immunoreactive dendritic processes in the 
amygdala. A: β1-adrenergic receptors (β1-AR cyt) are shown located within the cytoplasmic 
compartment of a CRF-immunoreactive dendrite (CRF-d). B: β1-adrenergic receptors (β1-
AR pm) are shown distributed along the plasma membrane of a CRF-immunoreactive 
dendrite (CRF-d). C: Some β1-adrenergic receptors are located within the cytoplasmic 
compartment, while some are located along the plasma membrane (β1-AR cyt + pm) of a 
CRF-immunoreactive dendrite (CRF-d). Arrowheads indicate immunogold labeling for β1-
adrenergic receptors within the cytoplasmic compartment, while arrows point to β1-
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adrenergic receptors along the plasma membrane. Scale bars: 0.50 μm. Abbreviations: ud, 
unlabeled dendrite; m, mitochondria; ut, unlabeled terminal.
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Table 1
Drug Treatment Groups
Drug Treatment: (14 days, 1x daily, 
i.p.)
24 hrs after Final Drug Treatment 
(i.p.)
44 hours after Final Drug Treatment 
(i.p.)
Group SS Saline (1 ml/kg) Saline (1 ml/kg) Saline (1 ml/kg)
Group CS Cocaine (20 mg/kg) Saline (1 ml/kg) Saline (1 ml/kg)
Group SB Saline (1 ml/kg) Betaxolol (5 mg/kg) Betaxolol (5 mg/kg)
Group CB Cocaine (20 mg/kg) Betaxolol (5 mg/kg) Betaxolol (5 mg/kg)
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